- Home
- FAF vs NUVL Comparison
FAF vs NUVL Comparison
Compare FAF & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAF
- NUVL
- Stock Information
- Founded
- FAF 1889
- NUVL 2017
- Country
- FAF United States
- NUVL United States
- Employees
- FAF N/A
- NUVL N/A
- Industry
- FAF Specialty Insurers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FAF Finance
- NUVL Health Care
- Exchange
- FAF Nasdaq
- NUVL Nasdaq
- Market Cap
- FAF 6.1B
- NUVL 5.6B
- IPO Year
- FAF N/A
- NUVL 2021
- Fundamental
- Price
- FAF $56.41
- NUVL $78.02
- Analyst Decision
- FAF Buy
- NUVL Strong Buy
- Analyst Count
- FAF 4
- NUVL 8
- Target Price
- FAF $75.00
- NUVL $115.50
- AVG Volume (30 Days)
- FAF 1.1M
- NUVL 429.5K
- Earning Date
- FAF 07-23-2025
- NUVL 05-08-2025
- Dividend Yield
- FAF 3.83%
- NUVL N/A
- EPS Growth
- FAF N/A
- NUVL N/A
- EPS
- FAF 1.52
- NUVL N/A
- Revenue
- FAF $6,285,800,000.00
- NUVL N/A
- Revenue This Year
- FAF $15.83
- NUVL N/A
- Revenue Next Year
- FAF $10.86
- NUVL N/A
- P/E Ratio
- FAF $37.12
- NUVL N/A
- Revenue Growth
- FAF 5.08
- NUVL N/A
- 52 Week Low
- FAF $51.85
- NUVL $55.54
- 52 Week High
- FAF $70.92
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FAF 43.31
- NUVL 59.59
- Support Level
- FAF $55.21
- NUVL $75.74
- Resistance Level
- FAF $56.23
- NUVL $79.08
- Average True Range (ATR)
- FAF 1.42
- NUVL 3.03
- MACD
- FAF 0.06
- NUVL 0.51
- Stochastic Oscillator
- FAF 30.98
- NUVL 80.43
About FAF First American Corporation (New)
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.